The World Heart Federation (WHF) reported on Tuesday the launch of a global study on cardiovascular disease and COVID-19 to better understand the outcomes and risk factors in COVID hospitalized patients and cardiovascular diseases (CVD).
WHF has launched a series of debates focused on how to unlock behavioural and societal change to beat CVD, which kills 17.9m people every year.
The federation added that the people with COVID-19 and heart disease are among those with the highest risk of death and severe complications. The heart might be adversely affected by the virus even in people without pre-existing conditions and the fear of the virus has led to a sharp decline in hospital visits by heart patients for routine and emergency care.
CVD is reportedly caused by smoking, diabetes, high blood pressure, obesity and air pollution and hence it is vital for governments and communities to regulate and make access to healthcare, healthy foods and a healthy way of life accessible and affordable to all people.
Heart Rhythm Society partners with Milestone Pharmaceuticals to offer new SVT patient resources
Haisco receives US FDA approval for anaesthetic Cipepofol
Avacta reports encouraging early efficacy signals for AVA6000 in salivary gland cancer at ASCO 2026
Circio and AaviGen partner to develop next-generation gene therapies for heart disease
Bayer's KERENDIA receives FDA priority review for type 1 diabetes and kidney disease treatment
Artivion completes acquisition of Endospan following FDA approval of NEXUS Aortic Arch System
AstraZeneca wins US approval for Baxfendy as first aldosterone synthase inhibitor for hypertension
GSK's Arexvy gains expanded approval in Japan for at-risk adults aged 18-49
Tenaya Therapeutics reports interim RIDGE-1 data showing reduced arrhythmia burden with TN-401